What is REVB's market cap?

Revelation Biosciences, Inc. (REVB) is a listed stock with a live quote. The latest market cap on this page is $2M.

Where is Revelation Biosciences, Inc. headquartered?

Revelation Biosciences, Inc. is headquartered in San Diego, CA.

How do I get REVB news from the API?

Call GET /v1/news?tickers=REVB. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.

How far back does REVB news go?

Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for REVB, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.

Is the REVB price on this page from the API?

The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.

Can I use the Pro plan commercially?

No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email sales@marketnewsapi.com.

REVB · NASDAQ

Revelation Biosciences, Inc.

$3.56 -0.56 (-13.54%)

Company overview

Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.

Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
Market cap: $2M
Employees: 8
Headquarters: San Diego, CA
Website: revbiosciences.com
CEO: James Rolke
Listed: November 17, 2020
P/E: -0.27
Dividend yield: 0.00%

Company financials

Revenue: $0.00
Gross profit: -$7,203
Operating income: -$10.1M
EBITDA: -$10M
Net income: -$9.9M
EPS: -$13.14
Total assets: $15M
Total debt: $759,044
Earnings yield: -369.10%

Price chart

REVB 1D NASDAQ O4.43H4.43L3.85C4.12-0.31 (-7.05%)Vol11.41K

News

Ticker	Type	Headline	Source	Published
REVBRevelation Biosciences, Inc.	Stock news	Revelation Biosciences Q3 net loss widens on Gemini development costs	Reuters	Nov 5, 5:41:15 PM ET
REVBRevelation Biosciences, Inc.	Press release	Revelation Biosciences, Inc. Announces Financial Results For the Three and Nine Months Ended September 30, 2026	Business Wire	Nov 5, 5:29:02 PM ET
REVBRevelation Biosciences, Inc.	Press release	Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026	Business Wire	Oct 16, 9:00:00 AM ET
REVBRevelation Biosciences, Inc.	Press release	Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study	Business Wire	Aug 19, 9:00:00 AM ET
REVBRevelation Biosciences, Inc.	Press release	Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026	Accesswire	Aug 6, 4:15:00 PM ET
REVBRevelation Biosciences, Inc.	Press release	Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury	Accesswire	Aug 3, 9:00:00 AM ET
REVBRevelation Biosciences, Inc.	Press release	Revelation Biosciences Announces Adoption of Stockholder Rights Plan	Accesswire	Jul 10, 4:05:00 PM ET
REVBRevelation Biosciences, Inc.	Press release	Revelation Biosciences Expands Acute Kidney Injury Advisory Board	Accesswire	Jun 1, 9:00:00 AM ET
REVBRevelation Biosciences, Inc.	Press release	Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders	Accesswire	May 11, 9:00:00 AM ET
REVBRevelation Biosciences, Inc.	Press release	Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026	Accesswire	May 7, 4:15:00 PM ET
REVBRevelation Biosciences, Inc.	Press release	Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board	Accesswire	Apr 6, 9:00:00 AM ET
REVBRevelation Biosciences, Inc.	Press release	Revelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical Study	Accesswire	Mar 30, 9:00:00 AM ET
REVBRevelation Biosciences, Inc.	Press release	REMINDER: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference	Accesswire	Mar 24, 9:00:00 AM ET
REVBRevelation Biosciences, Inc.	Press release	Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference	Accesswire	Mar 19, 9:00:00 AM ET
REVBRevelation Biosciences, Inc.	Stock news	Revelation Biosciences, Inc. (NASDAQ:REVB) Short Interest Update	Defense World	Feb 27, 4:30:51 AM ET
REVBRevelation Biosciences, Inc.	Press release	Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025	Accesswire	Feb 26, 4:15:00 PM ET
REVBRevelation Biosciences, Inc.	Press release	Revelation Biosciences Inc. Announces 1-for-4 Reverse Stock Split Effective January 28, 2026	Accesswire	Jan 26, 9:55:00 AM ET
REVBRevelation Biosciences, Inc.	Press release	Revelation Biosciences Inc. Announces Exercise of Warrants for $11 Million in Gross Proceeds	Accesswire	Jan 23, 2:10:00 PM ET
REVBRevelation Biosciences, Inc.	Stock news	Why Did Revelation Biosciences (REVB) Stock Jump Over 25% After-Hours?	Benzinga	Jan 23, 2:02:54 AM ET
REVBRevelation Biosciences, Inc.	Press release	Revelation Biosciences Reaches Agreement with FDA on Gemini Approval Pathway for AKI	Accesswire	Jan 21, 8:30:00 AM ET

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.